Cancer therapies

On this page:

• Akynzeo
• Bavencio^B,C,O
• Imfinzi^B,C
• Lartruvo^B,C,O
• Oncaspar^B,O
• Onivyde^P,O
• Portrazza^B,O
• Rydapt^P,O
• Tecentriq^B,C
• Tepadina^C,O

Akynzeo

(new active substance)

Medical ingredient:

Palonosetron Hydrochloride, Netupitant

Indication:

Prevention of nausea (feeling sick) and vomiting that may happen after taking certain anti-cancer medicines (chemotherapy).

For more information, see the Regulatory Decision Summary.

Bavencio^B,C,O

(new active substance)

Medical ingredient:

Avelumab

Indication:

Bavencio is a medicine used to treat a rare type of skin cancer that has spread called metastatic Merkel cell carcinoma in previously treated adults.

For more information, see the Regulatory Decision Summary.

Imfinzi^B,C

(new active substance)

Medical ingredient:

Durvalumab

Indication:

Imfinzi (durvalumab) is a medicine used to treat adults with a bladder cancer (called urothelial carcinoma) including cancer of the ureter, urethra or kidney pelvis.

For more information, see the Regulatory Decision Summary.

Lartruvo^B,C,O

(new active substance)

Medical ingredient:

Olaratumab

Indication:

Lartruvo is a cancer medicine used together with doxorubicin (another cancer medicine) to treat soft tissue sarcoma (a cancer of muscles, fat or other tissues) when treatment with radiation or surgery are not options.

For more information, see the Regulatory Decision Summary.

Oncaspar^B,O

Medical ingredient:

Pegaspargase

Indication:

Oncaspar is used to treat acute lymphoblastic leukaemia (ALL).

For more information, see the Regulatory Decision Summary.

Onivyde^P,O

Medical ingredient:

Irinotecan hydrochloride trihydrate

Indication:

Onivyde is used to treat adult patients with metastatic pancreatic cancer (cancer of the pancreas that has already spread elsewhere in the body).

Portrazza^B,O

(new active substance)

Medical ingredient:

Necitumumab

Indication:

Portrazza is a cancer medicine used in combination with gemcitabine and cisplatin (other anti-cancer medicines) for the treatment of patients with a type of advanced lung cancer (called squamous non-small cell lung cancer) who have not received prior chemotherapy for this condition.

For more information, see the Regulatory Decision Summary.

Rydapt^P,O

(new active substance)

Medical ingredient:

Midostaurin

Indication:

Rydapt is used in combination with other chemotherapy treatments to treat acute myeloid leukemia (AML) in adults who have a new diagnosis of a defect in a gene called FLT3.

For more information, see the Regulatory Decision Summary.

Tecentriq^B,C

(new active substance)

Medical ingredient:

Atezolizumab

Indication:

Tecentriq is used to treat a type of bladder cancer called urothelial carcinoma that cannot be removed by surgery or has spread to other parts of the body. Tecentriq is used after you have tried chemotherapy and it did not work or is no longer working.

For more information, see the Regulatory Decision Summary.

Tepadina^C,O

Medical ingredient:

Thiotepa

Indication:

Tepadina is used to treat adult patients with central nervous system (CNS) lymphoma. It is used in combination with other anticancer medicines and is followed by stem cell transplantation.

For more information, see the Regulatory Decision Summary.

Health Canada approved 17 new generic drugs for cancer.

Mammomat Inspiration

(novel technology)

Indication:

A medical device used for two-dimensional and three-dimensional mammograms to screen and diagnose breast cancer.

For more information, see the Summary Basis of Decision.

MRIdian Linac System

(novel technology)

Indication:

A combination MRI and linear accelerator system intended to provide stereotactic radiosurgery and precision radiotherapy for lesions, tumours, and conditions anywhere in the body where radiation treatment is indicated.

For more information, see the Summary Basis of Decision.

Health Canada released 14 risk communications for cancer.